Motiform Inc.

Overview

Updated: Sep 4, 2026

Company Overview

MO

- Base editing built on a proprietary, in-house-discovered enzyme core technology and AI-integrated R&D - ‘Gene editing’ has high industrial scalability, and timing that allows for early market leadership - Therapeutic development backed by deep clinical insight through collaboration with Asan Medical Center

Address

Headquarters :4F, 94-1 Gayang-ro, Dong-gu, Daejeon

Research Center :-

Website

https://motiform.bio/

Class

Pharmaceutical

Partnering Goals

Private

Investment Info

Investment History

Total 0

2025-11-00
Seed
-
Investor Amount
Deep Science Investment Fund 1 -

Investor	Amount
Deep Science Investment Fund 1	-

Shareholders

Founding Team

Deep Science Investment Fund No. 1

Funding Goal

Target StagePre-Series A

Team

Key People

CEO

Jungeum Kim

M.S. in Life Sciences, Seoul National University Former) Quotalab Director

CSO

Yongseop Kim

Chemistry, Seoul National University Ph.D. Current) Professor, University of Ulsan College of Medicine

Advisors

Private

Tech & Products

Technology Details

Private

Problem & Unmet Needs

Unmet CustomerNeeds

Existing CRISPR technology only works in actively dividing cells, and DNA double-strand breaks create unpredictable side-effectrisks. Precision single-base editing offers strong efficacy for genetic disease treatment, yet worldwide only about 3 teams hold this core technology, and none has yet reached commercialization Organelle base editing is an innovative field with no clinical precedentyet A need exists for curative treatments for degenerative and genetic diseases

Market Trends

2033

Projected to reach $15billion(approx. KRW 21 trillion)

Competitive Landscape

Ex vivo therapies such as Casgevy are already on the market, and competition over gene editing and delivery-vector patents isintensifying. Single-base editing technology, however, remains an early-stage field with few players

Pipeline

MF-101

Indication

Aging

Modality

Private

Sub-Modality

Private

Current Stage

Preclinical

CandidatePreclinicalINDPhase 1Phase 2Phase 3NDA

Patents & Papers

Papers

Paper Title

High-efficiency base editing for nuclear and mitochondrial DNA with an optimized DYW-like deaminase

Journal

Molecular

Published Year

Private

PMID

Private

Impact Factor

12.0

Paper Title

Emerging trends in prime editing for precision genome editing

Journal

Experimental & Molecular Medicine

Published Year

Private

PMID

Private

Impact Factor

12.9

Patents

Patent Title

Fusion protein comprising Cas protein and bacterial toxin, and its use

Status

Filed

Application Year

Private

Application Countries

KR/US/WO/EP/JP/CN

Patent Title

Fusion protein comprising Cas protein and bacterial toxin variant, and its use

Status

Filed

Application Year

Private

Application Countries

KR/WO

Patent Title

Fusion protein comprising a nucleic acid-binding protein and SsdA, and its use

Status

Filed

Application Year

Private

Application Countries

KR/WO

Latest News

Private

Overview

Company Overview

Motiform Inc.

Investment Info

Investment History

Shareholders

Funding Goal

Team

Key People

Advisors

Tech & Products

SsdAtox-based, highly versatile novel base editing enzyme(C>T

Technology Details

Problem & Unmet Needs

Unmet CustomerNeeds

Market Trends

2033

Competitive Landscape

Competitive Landscape

Pipeline

Patents & Papers

Papers

Patents

Latest News